Skip to main content
Top
Published in: Rheumatology International 12/2009

01-10-2009 | Original Article

Serum concentrations of formation (PINP) and resorption (Ctx) bone turnover markers in rheumatoid arthritis

Authors: Margaret Wisłowska, Danuta Jakubicz, Krystyna Stępień, Małgorzata Cicha

Published in: Rheumatology International | Issue 12/2009

Login to get access

Abstract

Joint inflammation in rheumatoid arthritis (RA) induces local periarticular osteoporosis. Generalised bone mineral density (BMD) decrease concerns approximately 50% of rheumatic patients. Both types of bone mass depletion can issue from cytokine-induced (TNF-α, IL-1, IL-6) osteoclasts’ activation, osteoprotegerin and its ligand’s (RANKL) function disorders, patients’ immobilisation and glucocorticosteroid (GCS) intake, as well as from hormonal alterations in postmenopausal women, predominate among RA individuals. The aim of the study was to compare serum concentrations of marker of bone formation—serum aminoterminal propeptide of type I collagen (PINP), and bone resorption, carboxy (C) terminal telopeptide (Ctx), bone turnover markers in RA and osteoarthritis (OA) patients and in RA groups of different disease activity, different degree of joint damage and the history of GCS intake. A total of 50 RA female patients and 50 women with knee OA were included in the study. Blood for morphology and biochemistry laboratory tests was taken. Joint X-rays to establish OA and RA diagnosis and the degree of RA progression, as well as DEXA BMD measurements were performed. PINP and Ctx concentrations were assessed. In RA patients the number of swollen and painful joints, the duration of morning stiffness, visual analogue scale values and Waaler–Rose’s test activity were recorded. The Disease Activity Index (DAS 28) was counted from the appropriate formula. No differences in bone turnover markers’ concentrations were noted neither between RA and OA patients nor between the RA group when compared to the one without the history of GCS use. Bone turnover markers’ concentrations in RA were proportional to the number of swollen and painful joints. However, no correlation was found between the markers’ concentrations and RA activity assessed by DAS 28 or by laboratory means. Ctx concentrations were higher in patients at II degree joint damage according to Larsen and Dale’s than at more advanced stages. Ctx concentrations decreased with the disease duration. Serum morphogenesis and resorption markers’ concentrations change in course of RA indicating the decrease in bone metabolic activity with the disease duration and progression. High RA activity and severity correlate with increased markers’ levels—the resorption one. The influence of GCS on bone metabolism in RA requires further study.
Literature
1.
go back to reference Suzuki Y, Tanihara M, Ichikawa Y et al (1995) Periarticular osteopenia in adjuvant-induced arthritis: role of interleukin-1 in decreased osteogenic and increased resorptive potential of bone marrow cells. Ann Rheum Dis 54:484–490. doi:10.1136/ard.54.6.484 PubMedCrossRef Suzuki Y, Tanihara M, Ichikawa Y et al (1995) Periarticular osteopenia in adjuvant-induced arthritis: role of interleukin-1 in decreased osteogenic and increased resorptive potential of bone marrow cells. Ann Rheum Dis 54:484–490. doi:10.​1136/​ard.​54.​6.​484 PubMedCrossRef
2.
go back to reference Dequeker J, Maenaut J, Verwilghen J et al (1995) Osteoporosis in rheumatoid arthritis. Clin Exp Rheumatol 13(Suppl 12):S21–S26PubMed Dequeker J, Maenaut J, Verwilghen J et al (1995) Osteoporosis in rheumatoid arthritis. Clin Exp Rheumatol 13(Suppl 12):S21–S26PubMed
3.
go back to reference Calvo MS, Eyre DR, Gunberg CM (1996) Molecular basis and clinical application of biological markers of bone turnover. Endocrinol Rev 17:333–368. doi:10.1210/er.17.4.333 Calvo MS, Eyre DR, Gunberg CM (1996) Molecular basis and clinical application of biological markers of bone turnover. Endocrinol Rev 17:333–368. doi:10.​1210/​er.​17.​4.​333
6.
go back to reference Van der Heijde DMFM, van’t Hof MA, van Riel PLCM et al (1993) Development of a disease activity score based on judgement in clinical practice by rheumatologists. J Rheumatol 20:579–581 Van der Heijde DMFM, van’t Hof MA, van Riel PLCM et al (1993) Development of a disease activity score based on judgement in clinical practice by rheumatologists. J Rheumatol 20:579–581
7.
go back to reference Larsen A, Dale K, Eek M (1977) Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 18:481–491 Larsen A, Dale K, Eek M (1977) Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 18:481–491
8.
go back to reference Robert R, Sokal F, Rohlf J (1986) Biometry. Freeman, New York, pp 354–359, 691–714 Robert R, Sokal F, Rohlf J (1986) Biometry. Freeman, New York, pp 354–359, 691–714
11.
go back to reference Demers LM, Kleerekoper M (1994) Recent advances in biochemical markers of bone turnover. Clin Chem 40:1994–1995PubMed Demers LM, Kleerekoper M (1994) Recent advances in biochemical markers of bone turnover. Clin Chem 40:1994–1995PubMed
14.
go back to reference Catrina AI, af Klint E, Ernestam S et al (2006) Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum 54:76–81. doi:10.1002/art.21528 PubMedCrossRef Catrina AI, af Klint E, Ernestam S et al (2006) Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum 54:76–81. doi:10.​1002/​art.​21528 PubMedCrossRef
16.
go back to reference Cortet B, Filipo RM, Pigny P et al (1998) Is bone turnover a determinant of bone mass in rheumatoid arthritis? J Rheumatol 25:2339–2344PubMed Cortet B, Filipo RM, Pigny P et al (1998) Is bone turnover a determinant of bone mass in rheumatoid arthritis? J Rheumatol 25:2339–2344PubMed
17.
19.
go back to reference Gough A, Sambroock P, Delvin J et al (1998) Osteoclastic activation in the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol 25:1282–1298PubMed Gough A, Sambroock P, Delvin J et al (1998) Osteoclastic activation in the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol 25:1282–1298PubMed
21.
go back to reference Nakayama H (2007) Osteoporosis in the patients with rheumatoid arthritis (3): the efficacy and the selection of the osteoporosis therapeutic drug. Clin Calcium 17:1607–1612PubMed Nakayama H (2007) Osteoporosis in the patients with rheumatoid arthritis (3): the efficacy and the selection of the osteoporosis therapeutic drug. Clin Calcium 17:1607–1612PubMed
23.
25.
go back to reference Garton MJ, Reid DM (1993) Bone mineral density of the hip and the spine in men with rheumatoid arthritis, effects of low dose corticosteroids. Arthritis Rheum 36:222–225PubMed Garton MJ, Reid DM (1993) Bone mineral density of the hip and the spine in men with rheumatoid arthritis, effects of low dose corticosteroids. Arthritis Rheum 36:222–225PubMed
26.
go back to reference Korczowska I, Olewicz-Gawlik A, Trefler J et al (2007) Does low-dose and short-term glucocorticoids treatment increase the risk of osteoporosis in rheumatoid arthritis female patients? Clin Rheumatol 27(5):565–572PubMedCrossRef Korczowska I, Olewicz-Gawlik A, Trefler J et al (2007) Does low-dose and short-term glucocorticoids treatment increase the risk of osteoporosis in rheumatoid arthritis female patients? Clin Rheumatol 27(5):565–572PubMedCrossRef
Metadata
Title
Serum concentrations of formation (PINP) and resorption (Ctx) bone turnover markers in rheumatoid arthritis
Authors
Margaret Wisłowska
Danuta Jakubicz
Krystyna Stępień
Małgorzata Cicha
Publication date
01-10-2009
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 12/2009
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-0867-x

Other articles of this Issue 12/2009

Rheumatology International 12/2009 Go to the issue